Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$20.89
-6.0%
$28.81
$20.19
$59.61
$994.16M1.41881,737 shs961,862 shs
Axonics, Inc. stock logo
AXNX
Axonics
$67.28
+0.3%
$67.80
$47.59
$69.68
$3.43B0.6731,079 shs398,176 shs
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$80.37
$82.48
$39.40
$89.76
$3.58B1.55626,604 shsN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
Glaukos Co. stock logo
GKOS
Glaukos
$106.51
+1.4%
$93.33
$49.19
$108.22
$5.35B1.08497,055 shs507,497 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
-5.99%-9.84%-21.11%-37.27%-56.78%
Axonics, Inc. stock logo
AXNX
Axonics
+0.25%+0.88%-3.40%-0.55%+29.86%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00%0.00%0.00%0.00%0.00%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%0.00%
Glaukos Co. stock logo
GKOS
Glaukos
+1.31%+7.07%+12.94%+15.85%+129.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
2.8798 of 5 stars
4.52.00.00.01.12.50.6
Axonics, Inc. stock logo
AXNX
Axonics
2.4288 of 5 stars
1.21.00.04.11.71.71.9
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
3.811 of 5 stars
2.43.00.04.42.92.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$49.78138.29% Upside
Axonics, Inc. stock logo
AXNX
Axonics
2.38
Hold$70.735.12% Upside
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
2.80
Moderate Buy$107.000.46% Upside

Current Analyst Ratings

Latest CMD, ATRC, AXNX, GKOS, and CSII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$57.00 ➝ $49.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $40.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$107.00 ➝ $112.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$108.00 ➝ $110.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00 ➝ $125.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$103.00 ➝ $110.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$108.00 ➝ $113.00
4/23/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$32.00
4/11/2024
Glaukos Co. stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $100.00
4/10/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$399.24M2.49N/AN/A$9.84 per share2.12
Axonics, Inc. stock logo
AXNX
Axonics
$366.38M9.37$0.13 per share531.32$12.29 per share5.47
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$1.02B3.52$3.38 per share23.78$17.31 per share4.64
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
Glaukos Co. stock logo
GKOS
Glaukos
$314.71M16.99N/AN/A$8.98 per share11.86

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.80N/AN/AN/A-8.98%-7.82%-6.02%7/23/2024 (Estimated)
Axonics, Inc. stock logo
AXNX
Axonics
-$6.09M-$0.32N/A96.11N/A-4.12%-2.58%-2.32%7/25/2024 (Estimated)
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$13.71M$1.6569.2828.911.634.72%12.13%4.45%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.88N/AN/AN/A-43.15%-24.69%-12.27%8/7/2024 (Estimated)

Latest CMD, ATRC, AXNX, GKOS, and CSII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.23-$0.25-$0.02-$0.22$106.86 million$108.90 million      
5/1/2024Q1 2024
Glaukos Co. stock logo
GKOS
Glaukos
-$0.58-$0.70-$0.12-$0.58$79.60 million$85.60 million    
4/30/2024Q1 2024
Axonics, Inc. stock logo
AXNX
Axonics
-$0.06-$0.38-$0.32-$0.38$89.79 million$91.41 million
2/28/2024Q4 2023
Axonics, Inc. stock logo
AXNX
Axonics
$0.06$0.13+$0.07$0.13$107.33 million$109.70 million
2/21/2024Q4 2023
Glaukos Co. stock logo
GKOS
Glaukos
-$0.56-$0.63-$0.07-$0.51$81.00 million$82.40 million    
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$0.210.26%N/A12.73%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.15
3.57
2.66
Axonics, Inc. stock logo
AXNX
Axonics
N/A
9.96
8.98
Cantel Medical Corp. stock logo
CMD
Cantel Medical
1.16
2.72
2.00
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
Glaukos Co. stock logo
GKOS
Glaukos
0.78
5.38
4.78

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Axonics, Inc. stock logo
AXNX
Axonics
99.48%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
84.13%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
Glaukos Co. stock logo
GKOS
Glaukos
99.04%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Axonics, Inc. stock logo
AXNX
Axonics
1.85%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
10.70%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
Glaukos Co. stock logo
GKOS
Glaukos
6.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20047.59 million46.83 millionOptionable
Axonics, Inc. stock logo
AXNX
Axonics
79751.02 million50.07 millionOptionable
Cantel Medical Corp. stock logo
CMD
Cantel Medical
3,66944.51 millionN/AOptionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
Glaukos Co. stock logo
GKOS
Glaukos
90750.19 million46.98 millionOptionable

CMD, ATRC, AXNX, GKOS, and CSII Headlines

SourceHeadline
Glaukos (NYSE:GKOS) Sets New 52-Week High Following Analyst UpgradeGlaukos (NYSE:GKOS) Sets New 52-Week High Following Analyst Upgrade
americanbankingnews.com - May 3 at 1:44 AM
Glaukos (NYSE:GKOS) PT Raised to $112.00 at BTIG ResearchGlaukos (NYSE:GKOS) PT Raised to $112.00 at BTIG Research
marketbeat.com - May 2 at 2:31 PM
Buy Rating Affirmed for Glaukos on Strong Q1 Performance and Promising iDose ProspectsBuy Rating Affirmed for Glaukos on Strong Q1 Performance and Promising iDose Prospects
markets.businessinsider.com - May 2 at 12:49 PM
Glaukos Corporation (NYSE:GKOS) Q1 2024 Earnings Call TranscriptGlaukos Corporation (NYSE:GKOS) Q1 2024 Earnings Call Transcript
msn.com - May 2 at 12:49 PM
Glaukos (NYSE:GKOS) Reaches New 1-Year High After Analyst UpgradeGlaukos (NYSE:GKOS) Reaches New 1-Year High After Analyst Upgrade
marketbeat.com - May 2 at 10:51 AM
Glaukos (NYSE:GKOS) Rating Reiterated by Truist FinancialGlaukos (NYSE:GKOS) Rating Reiterated by Truist Financial
marketbeat.com - May 2 at 10:30 AM
Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/YGlaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y
zacks.com - May 2 at 10:16 AM
Glaukos Corp (GKOS) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...Glaukos Corp (GKOS) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...
finance.yahoo.com - May 2 at 7:49 AM
Q1 2024 Glaukos Corp Earnings Call TranscriptQ1 2024 Glaukos Corp Earnings Call Transcript
gurufocus.com - May 2 at 1:01 AM
Glaukos Corp (GKOS) Earnings Dates & ReportsGlaukos Corp (GKOS) Earnings Dates & Reports
investing.com - May 2 at 12:43 AM
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
msn.com - May 2 at 12:43 AM
Glaukos: Q1 Earnings SnapshotGlaukos: Q1 Earnings Snapshot
timesunion.com - May 1 at 7:42 PM
Glaukos Announces First Quarter 2024 Financial ResultsGlaukos Announces First Quarter 2024 Financial Results
finance.yahoo.com - May 1 at 7:42 PM
Glaukos Corp (GKOS) Q1 2024 Earnings: Misses Analyst EPS Forecast, Surpasses Revenue ExpectationsGlaukos Corp (GKOS) Q1 2024 Earnings: Misses Analyst EPS Forecast, Surpasses Revenue Expectations
finance.yahoo.com - May 1 at 7:42 PM
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue EstimatesGlaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
zacks.com - May 1 at 6:51 PM
Heres what to expect from Glaukoss earnings reportHere's what to expect from Glaukos's earnings report
markets.businessinsider.com - April 30 at 7:15 PM
Glaukos Co. (NYSE:GKOS) Short Interest Down 5.7% in AprilGlaukos Co. (NYSE:GKOS) Short Interest Down 5.7% in April
marketbeat.com - April 30 at 1:36 PM
Jennison Associates LLC Makes New Investment in Glaukos Co. (NYSE:GKOS)Jennison Associates LLC Makes New Investment in Glaukos Co. (NYSE:GKOS)
marketbeat.com - April 29 at 5:43 AM
Glaukos Co. (NYSE:GKOS) Holdings Lifted by State of New Jersey Common Pension Fund DGlaukos Co. (NYSE:GKOS) Holdings Lifted by State of New Jersey Common Pension Fund D
marketbeat.com - April 27 at 8:22 AM
Glaukos (NYSE:GKOS) Reaches New 1-Year High at $102.60Glaukos (NYSE:GKOS) Reaches New 1-Year High at $102.60
americanbankingnews.com - April 26 at 6:47 AM
Glaukos (NYSE:GKOS) Reaches New 52-Week High at $102.60Glaukos (NYSE:GKOS) Reaches New 52-Week High at $102.60
marketbeat.com - April 24 at 1:55 PM
Glaukos (GKOS) Set to Announce Quarterly Earnings on WednesdayGlaukos (GKOS) Set to Announce Quarterly Earnings on Wednesday
americanbankingnews.com - April 24 at 4:58 AM
Glaukos’ Tiny Medical Devices Fuel Expansion for OphthalmologyGlaukos’ Tiny Medical Devices Fuel Expansion for Ophthalmology
ocbj.com - April 23 at 12:57 AM
Glaukos (NYSE:GKOS) Trading Up 3.4%Glaukos (NYSE:GKOS) Trading Up 3.4%
marketbeat.com - April 19 at 1:58 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Axonics logo

Axonics

NASDAQ:AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Cantel Medical logo

Cantel Medical

NYSE:CMD
Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.
Cardiovascular Systems logo

Cardiovascular Systems

NASDAQ:CSII
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.
Glaukos logo

Glaukos

NYSE:GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.